P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants.
Xuening LiMiwa HaranakaHui LiPei LiuHuijun ChenStefan KleinStefanie ReifKlaus FranckeChristian FriedrichKazuhito OkumuraPublished in: Clinical pharmacokinetics (2024)
ClinicalTrials.gov identifier numbers: NCT04265781 and NCT04802343.